Marita Yaghi

Dr. Marita Yaghi

Cleveland Clinic
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2022 in Cancers
Verified
Journal Article
Open access
PDF file
MZMaroun Bou Zerdan
Maroun Bou Zerdan
TGTala Ghorayeb
Tala Ghorayeb
FSFares Saliba
Fares Saliba
SASabine Allam
Sabine Allam
MZMorgan Bou Zerdan
Morgan Bou Zerdan
ZNZeina Nahleh
Zeina Nahleh
Breast cancer (BC) is the most common malignancy affecting women. It is a highly heterogeneous disease broadly defined by the differential expression of cell surface receptors. In the United States, triple negative breast cancer (TNBC) represents 15 to 20% of all BC. When compared with other subtypes of BC, TNBC tends to present in younger women, and has a higher mortality rate of 40% in advanced stages within the first 5 years after diagnosis. TNBC has historically had limited treatment options when compared to other types of BC. The mainstay of treatment for TNBC remains cytotoxic chemotherapy despite the emergence of new biologic and targeted agents. Defining the specific tumor molecular profile including PDL-1 and androgen receptor testing is expanding treatment options in the clinical setting. Identifying more targetable, novel biomarkers that may better define therapeutic targets or prognostic markers is currently underway. TNBC nomenclature is expected to be updated in favor of other nomenclature which would help direct therapy, and further redefine TNBC’s heterogeneity. Given the continuous advances in the field of TNBC, this review assesses the latest developments in basic characterization, subtyping, and treatment of TNBC, including novel drug developments with antibody-drug conjugates, immune checkpoint inhibitors, PARP inhibitors and androgen receptor targeted agents. Future trials are necessary in the face of these innovations to further support the use of new therapies in TNBC and the detection of the appropriate biomarkers.

29 December 2021 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
LHLoren E. Hernandez
Loren E. Hernandez
NMNoreen Mohsin
Noreen Mohsin
MYMarita Yaghi
Marita Yaghi
FFFabio Stefano Frech
Fabio Stefano Frech
IDIsabella Dreyfuss
Isabella Dreyfuss
KNKeyvan Nouri
Keyvan Nouri

17 June 2022 in JAAD International
Verified
Journal Article
Open access
MYMarita Yaghi
Marita Yaghi
PBPaul Benedetto
Paul Benedetto
JGJohn Greskovich
John Greskovich
RHRoger Haber
Roger Haber
BDBarbara Dominguez
Barbara Dominguez
RARafael Arteta-Bulos
Rafael Arteta-Bulos
Using the National Cancer Database, we introduce the findings of a retrospective investigation of the largest cohort of cases with Merkel cell carcinoma (N = 20,829). A decreasing proportion of stage I (P = .0004) and stage II (P = .0065) Merkel cell carcinoma among skin cancers was complemented by an increasing proportion of stage III disease (P < .0001). A predominance of non-Hispanic White (96.4%), male (62.6%) patients with a mean age of 74.5 ± 10.8 years and Medicare coverage (73.5%) was observed. Stage I was the most common presenting stage at diagnosis (29.2%), followed by stages II (12.7%), III (11.0%), and IV (3.8%). Most Merkel cell carcinoma tumors grew outside the head and neck (53.4%) and showed a nodular growth pattern (66.0%) but no extracapsular lymph node (90.5%) or lymphovascular involvement (63.8%). Narrow-margin excision and radiation therapy (RT) were used in 75.2% and 56.3% of tumors, respectively. Wide-margin excision lead to improved overall survival (P < .001) versus narrow-margin excision, particularly in stage III (difference in the median overall survival rate [ΔmOS], 23.7 months; P < .001). RT showed a significant OS benefit (P =.006), most pronounced in stage II (ΔmOS, 37.8 months) followed by stage I (ΔmOS, 16.1 months; P < .001). The survival benefit with primary-site RT (ΔmOS, 24.0 months) was higher than that with primary-site/lymph node RT (ΔmOS, 5.2 months; P < .001). Wide-margin excision independently predicted improved OS (hazard ratio, 0.577; 95% CI, 0.403-0.826; P = .003) versus narrow-margin excision and RT predicted better OS (hazard ratio, 0.608; 95% CI, 0.424-0.873; P = .007) versus no RT on multivariable analysis.

10 October 2024 in Lasers in Medical Science
Verified
Journal Article
Open access
PDF file
SGSimonetta Ines Gaumond
Simonetta Ines Gaumond
RARama Abdin
Rama Abdin
MYMarita Yaghi
Marita Yaghi
RMRami H. Mahmoud
Rami H. Mahmoud
MRMario Rodriguez
Mario Rodriguez
JJJoaquín J. Jiménez
Joaquín J. Jiménez
Acne has a prevalence of over 90% among adolescents, and subsequently progresses to acne scarring in approximately 47% of cases. Due to the severe psychological and social ramifications acne scarring has on patients, there is a need for more effective treatments. Platelet-rich plasma (PRP), an autologous preparation enriched with growth factors, cytokines, and chemokines, has shown efficacy in promoting wound healing and tissue remodeling in dermatology. Recent evidence suggests that the efficacy of PRP may be enhanced when combined with laser therapy, which induces controlled tissue damage through photo-thermolysis thereby promoting tissue remodeling and epidermal regeneration. The microchannels created by laser treatments are thought to allow deeper penetration of PRP into the skin, potentially increasing its therapeutic effects. This review aims to analyze the combined use of PRP and laser therapy for treating acne scarring by examining randomized control trials from the past decade indexed on PubMed. Six studies met our inclusion criteria and were included in this review. The findings of this review support the hypothesis that combining PRP with laser therapy offers superior clinical results compared to monotherapy, providing a more effective approach to managing acne scarring.

26 May 2022 in Dermatologic Therapy
Verified
Journal Article
Closed access
LHLoren E. Hernandez
Loren E. Hernandez
NMNoreen Mohsin
Noreen Mohsin
FFFabio Frech
Fabio Frech
ADAshley Vander Does
Ashley Vander Does
IDIsabella Dreyfuss
Isabella Dreyfuss
KNKeyvan Nouri
Keyvan Nouri

26 August 2021 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
NBNadeem Bilani
Nadeem Bilani
MYMarita Yaghi
Marita Yaghi
IJIktej Singh Jabbal
Iktej Singh Jabbal
LELeah Elson
Leah Elson
EEElizabeth Blessing Elimimian
Elizabeth Blessing Elimimian
ZNZeina Nahleh
Zeina Nahleh